Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - Accuray Incorporated (ARAY-NASDAQ) |
|
|
“If you are a patient, you should remember that Accuray’s CyberKnife is an alternative to surgery. It’s a non-invasive, painless out-patient procedure. The Cyberknife can treat inoperable tumors, and even if operable, you don’t want to cut open the patient, crack open their rib cage, and deflate their lungs in order to treat a lung tumor or invasively treat a tumor that is wrapped around the spine. It may be inoperable in that case. Our technology offers the means to deliver high doses of radiation...” - Robert E. McNamara (ARAY) (Interview published May 30, 2008) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | SERVICES | HOME PAGE |
|
Presentations at Leading Neurosurgery
Meeting Highlight Benefits of CyberKnife Radiosurgery for the
Treatment of CNS Indications
Benefits of Frameless Delivery and Fractionation Demonstrated in Favorable Response Rates and Hearing Preservation At this year's AANS meeting, doctors presented on their experience treating intracranial tumors and spinal arterial venous malformations (AVMs) with CyberKnife radiosurgery. Key findings include: -- These presentations further underscore the unique capabilities of the CyberKnife System, which were recently showcased in a supplement issued by Neurosurgery, the official journal of the Congress of Neurological Surgeons. The supplement, titled "CyberKnife Stereotactic Robotic Radiosurgery", comprised 15 peer-reviewed papers dedicated to CyberKnife radiosurgery experience treating brain and spine indications. As a non-invasive treatment for intracranial and spinal tumors, the CyberKnife System does not require the use of stabilizing head frames to achieve the sub-millimeter accuracy required for radiosurgery procedures, providing maximum patient comfort. For this reason treatment can easily be delivered in a single fraction or multiple fractions (sessions). This allows the dose to be spread over two to five sessions, which may reduce the risk of damage to sensitive structures such as the cranial nerves, the eyes or the spinal cord. The frameless nature of the CyberKnife System also easily enables treatment of both intracranial tumors and tumors at all levels of the spine. "CNS applications continue to be an important area for CyberKnife
radiosurgery, with more than 40,000 intracranial and spine patients
treated to date worldwide," said CyberKnife radiosurgery offers a non-surgical treatment option for benign and cancerous tumors, as well as other conditions such as trigeminal neuralgia and AVMs. About the CyberKnife(R) Robotic Radiosurgery System The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames. About Safe Harbor Statement The foregoing may contain certain forward-looking statements that
involve risks and uncertainties, including uncertainties associated
with the medical device industry. Except for the historical
information contained herein, the matters set forth in this press
release, including statements relating to clinical studies,
commercialization of products, and regulatory review and approval
are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements speak only as of the date the
statements are made and are based on information available at the
time those statements are made and/or management's good faith belief
as of that time with respect to future events. You should not put
undue reliance on any forward-looking statements. Important factors
that could cause actual performance and results to differ materially
from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our
products with complementary technology; and other risks detailed
from time to time under the heading "Risk Factors" in our report on
Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q
filed on Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
SOURCE
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.